Catalogo Articoli (Spogli Riviste)

HELP
ATTENZIONE: attualmente gli articoli Current Contents (fonte ISI) a partire dall'anno 2002 sono consultabili sulla Risorsa On-Line

Le informazioni sugli articoli di fonte ISI sono coperte da copyright

La ricerca find articoli where soggetti phrase all words 'CYP1A2' sort by level,fasc_key/DESCEND, pagina_ini_num/ASCEND ha restituito 287 riferimenti
Si mostrano 100 riferimenti a partire da 1
Selezionare un intervallo

Per ulteriori informazioni selezionare i riferimenti di interesse.

    1. Caubet, MS; Elbast, W; Dubuc, MC; Brazier, JL
      Analysis of urinary caffeine metabolites by HPLC-DAD: the use of metabolicratios to assess CYP1A2 enzyme activity

      JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS
    2. Wu, XZ; Noda, A; Noda, H; Imamura, Y
      Side-chain metabolism of propranolol: involvement of monoamine oxidase andaldehyde reductase in the metabolism of N-desisopropylpropranolol to propranolol glycol in rat liver

      COMPARATIVE BIOCHEMISTRY AND PHYSIOLOGY C-TOXICOLOGY & PHARMACOLOGY
    3. Gonzalez, FJ; Kimura, S
      Understanding the role of xenobiotic-metabolism in chemical carcinogenesisusing gene knockout mice

      MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
    4. Desai, HD; Seabolt, J; Jann, MW
      Smoking in patients receiving psychotropic medications - A pharmacokineticperspective

      CNS DRUGS
    5. Diliberto, JJ; DeVito, MJ; Ross, GD; Birnbaum, LS
      Subchronic exposure of [H-3]-2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) infemale B6C3F1 mice: Relationship of steady-state levels to disposition andmetabolism

      TOXICOLOGICAL SCIENCES
    6. Renwick, AG; Dorne, JLCM; Walton, K
      Pathway-related factors: The potential for human data to improve the scientific basis of risk assessment

      HUMAN AND ECOLOGICAL RISK ASSESSMENT
    7. Han, XM; Ou-Yang, DS; Lu, PX; Jiang, CH; Shu, Y; Chen, XP; Tan, ZR; Zhou, HH
      Plasma caffeine metabolite ratio (17X/137X) in vivo associated with G-2964A and C734A polymorphisms of human CYP1A2

      PHARMACOGENETICS
    8. Corchero, J; Pimprale, S; Kimura, S; Gonzalez, FJ
      Organization of the CYP1A cluster on human chromosome 15: implications forgene regulation

      PHARMACOGENETICS
    9. Lelouet, H; Bechtel, YC; Paintaud, G; Brientini, MP; Miguet, JP; Bechtel, PR
      Caffeine metabolism in a group, of 67 patients with primary biliary cirrhosis

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    10. Bu, HZ; Knuth, K; Magis, L; Teitelbaum, P
      High-throughput cytochrome P450 (CYP) inhibition screening via a cassette probe-dosing strategy - V. Validation of a direct injection/on-line guard cartridge extraction-tandem mass spectrometry method for CYP1A2 inhibition assessment

      EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
    11. Matsunaga, N; Hattori, K; Iizasa, H; Kizu, J; Takanaka, A; Nakashima, E
      Application of the PKCYP-test in cases of altered CYP1A2 for multiple CYP systems in rat models of disease

      BIOLOGICAL & PHARMACEUTICAL BULLETIN
    12. Skene, DJ; Papagiannidou, E; Hashemi, E; Snelling, J; Lewis, DFV; Fernandez, M; Ioannides, C
      Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices

      JOURNAL OF PINEAL RESEARCH
    13. Rodriguez, JB
      Pharmacogenetics in clinical pharmacology: Present and future

      METHODS AND FINDINGS IN EXPERIMENTAL AND CLINICAL PHARMACOLOGY
    14. Gonzalez, FJ
      The use of gene knockout mice to unravel the mechanisms of toxicity and chemical carcinogenesis

      TOXICOLOGY LETTERS
    15. Ingelman-Sundberg, M
      Genetic variability in susceptibility and response to toxicants

      TOXICOLOGY LETTERS
    16. Sofowora, GG; Choo, EF; Mayo, G; Shyr, Y; Wilkinson, GR
      In vivo inhibition of human CYP1A2 activity by oltipraz

      CANCER CHEMOTHERAPY AND PHARMACOLOGY
    17. Koch, KM; Ricci, BM; Hedayetullah, NS; Jewell, D; Kersey, KE
      Effect of alosetron on theophylline pharmacokinetics

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    18. Simon, T; Becquemont, L; Hamon, B; Nouyrigat, E; Chodjania, Y; Poirier, JM; Funck-Brentano, C; Jaillon, P
      Variability of cytochrome P450 1A2 activity over time in young and elderlyhealthy volunteers

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    19. Wei, C; Caccavale, RJ; Kehoe, JJ; Thomas, PE; Iba, MM
      CYP1A2 is expressed along with CYP1A1 in the human lung (vol 164, pg 25, 2001)

      CANCER LETTERS
    20. Wei, C; Cacavale, RJ; Kehoe, JJ; Thomas, PE; Iba, MM
      CYP1A2 is expressed along with CYP1A1 in the human lung

      CANCER LETTERS
    21. Walton, K; Dorne, JL; Renwick, AG
      Uncertainty factors for chemical risk assessment: interspecies differencesin the in vivo pharmacokinetics and metabolism of human CYP1A2 substrates

      FOOD AND CHEMICAL TOXICOLOGY
    22. Dorne, JLCM; Walton, K; Renwick, AG
      Uncertainty factors for chemical risk assessment: human variability in thepharmacokinetics of CYP1A2 probe substrates

      FOOD AND CHEMICAL TOXICOLOGY
    23. Meyer, JM
      Individual changes in clozapine levels after smoking cessation: Results and a predictive model

      JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY
    24. Schulz, TG; Thiel, R; Neubert, D; Brassil, PJ; Schulz-Utermoehl, T; Boobis, AR; Edwards, RJ
      Assessment of P450 induction in the marmoset monkey using targeted anti-peptide antibodies

      BIOCHIMICA ET BIOPHYSICA ACTA-PROTEIN STRUCTURE AND MOLECULAR ENZYMOLOGY
    25. Ozdemir, V; Basile, VS; Masellis, M; Kennedy, JL
      Pharmacogenetic assessment of antipsychotic-induced movement disorders: contribution of the dopamine D3 receptor and cytochrome P450 1A2 genes

      JOURNAL OF BIOCHEMICAL AND BIOPHYSICAL METHODS
    26. Eap, CB; Bondolfi, G; Zullino, D; Bryois, C; Fuciec, M; Savary, L; Jonzier-Perey, M; Baumann, P
      Pharmacokinetic drug interaction potential of risperidone with cytochrome P450 isozymes as assessed by the dextromethorphan, the caffeine, and the mephenytoin test

      THERAPEUTIC DRUG MONITORING
    27. Salmela, KS; Tsyrlov, IB; Lieber, CS
      Azide inhibits human cytochrome P-4502E1, 1A2, and 3A4

      ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
    28. Bapiro, TE; Egnell, AC; Hasler, JA; Masimirembwa, CM
      Application of higher throughput screening (HTS) inhibition assays to evaluate the interaction of antiparasitic drugs with cytochrome P450S

      DRUG METABOLISM AND DISPOSITION
    29. Nebert, DW; Roe, AL
      Ethnic and genetic differences in metabolism genes and risk of toxicity and cancer

      SCIENCE OF THE TOTAL ENVIRONMENT
    30. Kappers, WA; Edwards, RJ; Murray, S; Boobis, AR
      Diazinon is activated by CYP2C19 in human liver

      TOXICOLOGY AND APPLIED PHARMACOLOGY
    31. Bray, BJ; Rosengren, RJ
      Retinol potentiates acetaminophen-induced hepatotoxicity in the mouse: Mechanistic studies

      TOXICOLOGY AND APPLIED PHARMACOLOGY
    32. Smith, AG; Clothier, B; Carthew, P; Childs, NL; Sinclair, PR; Nebert, DW; Dalton, TP
      Protection of the Cyp1a2(-/-) null mouse against uroporphyria and hepatic injury following exposure to 2,3,7,8-tetrachlorodibenzo-p-dioxin

      TOXICOLOGY AND APPLIED PHARMACOLOGY
    33. Vakharia, DD; Liu, N; Pause, R; Fasco, M; Bessette, E; Zhang, QY; Kaminsky, LS
      Effect of metals on polycyclic aromatic hydrocarbon induction of CYP1A1 and CYP1A2 in human hepatocyte cultures

      TOXICOLOGY AND APPLIED PHARMACOLOGY
    34. Janus, K; Antoszek, J; Suszycki, S
      The effect of short-term starvation or water deprivation caffeine pharmacokinetics in calves

      RESEARCH IN VETERINARY SCIENCE
    35. Sy, SKB; Tang, BK; Pastrakuljic, A; Roberts, EA; Kalow, W
      Detailed characterization of experimentally derived human hepatic CYP1A1 activity and expression using differential inhibition of ethoxyresorufin O-deethylation by fluvoxamine

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    36. Kivisto, KT; Wang, JS; Backman, JT; Nyman, L; Taavitsainen, P; Anttila, M; Neuvonen, PJ
      Selegiline pharmacokinetics are unaffected by the CYP3A4 inhibitor itraconazole

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    37. Facciola, G; Hidestrand, M; von Bahr, C; Tybring, G
      Cytochrome P-450 isoforms involved in melatonin metabolism in human liver microsomes

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    38. Hammons, GJ; Yan-Sanders, Y; Jin, B; Blann, E; Kadlubar, FF; Lyn-Cook, BD
      Specific site methylation in the 5 '-flanking region of CYP1A2 - Interindividual differences in human livers

      LIFE SCIENCES
    39. Groeneveld, GJ; van Kan, HJM; Torano, JS; Veldink, JH; Guchelaar, HJ; Wokke, JHJ; van den Berg, LH
      Inter- and intraindividual variability of riluzole serum concentrations inpatients with ALS

      JOURNAL OF THE NEUROLOGICAL SCIENCES
    40. Court, MH; Duan, SX; Von Moltke, LL; Greenblatt, DJ; Patten, CJ; Miners, JO; Mackenzie, PI
      Interindividual variability in acetaminophen glucuronidation by human liver microsomes: Identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    41. Zhu, B; Ou-Yang, DS; Chen, XP; Huang, SL; Tan, ZR; He, N; Zhou, HH
      Assessment of cytochrome P450 activity by a five-drug cocktail approach

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    42. Tsutsumi, K; Kotegawa, T; Matsuki, S; Tanaka, Y; Ishii, Y; Kodama, Y; Kuranari, M; Miyakawa, I; Nakano, S
      The effect of pregnancy on cytochrome P4501A2, xanthine oxidase, and N-acetyltransferase activities in humans

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    43. Hartter, S; Ursing, C; Morita, S; Tybring, G; von Bahr, C; Christensen, M; Rojdmark, S; Bertilsson, L
      Orally given melatonin may serve as a probe drug for cytochrome P450 1A2 activity in vivo: A pilot study

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    44. Kusumoto, M; Ueno, K; Oda, A; Takeda, K; Mashimo, K; Takaya, K; Fujimura, Y; Nishihori, T; Tanaka, K
      Effect of fluvoxamine on the pharmacokinetics of mexiletine in healthy Japanese men

      CLINICAL PHARMACOLOGY & THERAPEUTICS
    45. Tantcheva-Poor, I; Servera-Llaneras, M; Scharffetter-Kochanek, K; Fuhr, U
      Liver cytochrome P450CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients

      BRITISH JOURNAL OF DERMATOLOGY
    46. Baker, JR; Satarug, S; Reilly, PEB; Edwards, RJ; Ariyoshi, N; Kamataki, T; Moore, MR; Williams, DJ
      Relationships between non-occupational cadmium exposure and expression of nine cytochrome P450 forms in human liver and kidney cortex samples

      BIOCHEMICAL PHARMACOLOGY
    47. Zaccaro, C; Sweitzer, S; Pipino, S; Gorman, N; Sinclair, PR; Sinclair, JF; Nebert, DW; De Matteis, F
      Role of cytochrome P450 1A2 in bilirubin degradation - Studies in Cyp1a2 (-/-) mutant mice

      BIOCHEMICAL PHARMACOLOGY
    48. Long, L; Moschel, RC; Dolan, ME
      Debenzylation of O-6-benzyl-8-oxoguanine in human liver: implications for O-6-benzylguanine metabolism

      BIOCHEMICAL PHARMACOLOGY
    49. Sugihara, K; Kitamura, S; Yamada, T; Ohta, S; Yamashita, K; Yasuda, M; Fujii-Kuriyama, Y
      Aryl hydrocarbon receptor (AhR)-mediated induction of xanthine oxidase/xanthine dehydrogenase activity by 2,3,7,8-tetrachlorodibenzo-p-dioxin

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    50. Liu, N; Zhang, QY; Vakharia, D; Dunbar, D; Kaminsky, LS
      Induction of CYP1A by benzo[k]fluoranthene in human hepatocytes: CYP1A1 orCYP1A2?

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    51. Aoki, J; Sato, M; Itakura, T
      An eel cytochrome P450 1A gene having no XRE sequences in its 5 ' upstreamregion of 1600 bp

      MARINE BIOTECHNOLOGY
    52. MacLeod, SL; Nowell, S; Massengill, J; Jazieh, A; McClure, G; Plaxco, J; Kadlubar, FF; Lang, NP
      Cancer therapy and polymorphisms of cytochromes P450

      CLINICAL CHEMISTRY AND LABORATORY MEDICINE
    53. Basile, VS; Ozdemir, V; Masellis, M; Walker, ML; Heltzer, HY; Lieberman, JA; Potkin, SG; Alva, G; Kalow, W; Macciardi, FM; Kennedy, JL
      A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia

      MOLECULAR PSYCHIATRY
    54. Hurst, CH; DeVito, MJ; Birnbaum, LS
      Tissue disposition of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in maternal and developing Long-Evans rats following subchronic exposure

      TOXICOLOGICAL SCIENCES
    55. Hurst, CH; DeVito, MJ; Setzer, RW; Birnbaum, LS
      Acute administration of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in pregnant Long Evans rats: Association of measured tissue concentrations with developmental effects

      TOXICOLOGICAL SCIENCES
    56. Aitchison, KJ; Gonzalez, FJ; Quattrochi, LC; Sapone, A; Zhao, JH; Zaher, H; Elizondo, G; Bryant, C; Munro, J; Collier, DA; Makoff, AJ; Kerwin, RW
      Identification of novel polymorphisms in the 5 ' flanking region of CYP1A2, characterization of interethnic variability, and investigation of their functional significance

      PHARMACOGENETICS
    57. Rettie, AE; Lang, DH
      Can caffeine metabolism be used as an in-vivo probe for human flavin-containing monooxygenase activity?

      PHARMACOGENETICS
    58. Zaigler, M; Rietbrock, S; Szymanski, J; Dericks-Tan, JSE; Staib, AH; Fuhr, U
      Variation of CYP1A2-dependent caffeine metabolism during menstrual cycle in healthy women

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    59. Bechtel, YC; Haffen, E; Lelouet, H; Brientini, MP; Paintaud, G; Miguet, JP; Bechtel, PR
      Relationship between the severity of alcoholic liver cirrhosis and the metabolism of caffeine in 226 patients

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    60. Zaigler, M; Tantcheva-Poor, I; Fuhr, U
      Problems and perspectives of phenotyping for drug-metabolizing enzymes in man

      INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
    61. Thatcher, NJ; Edwards, RJ; Lemoine, NR; Doehmer, J; Davies, DS
      The potential of acetaminophen as a prodrug in gene-directed enzyme prodrug therapy

      CANCER GENE THERAPY
    62. Cui, L; Takahashi, S; Tada, M; Kato, K; Yamada, Y; Kohri, K; Shirai, T
      Immunohistochemical detection of carcinogen-DNA adducts in normal human prostate tissues transplanted into the subcutis of athymic nude mice: Resultswith 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 3,2 '-dimethyl-4-aminobiphenyl (DMAB) and relation to cytochrome P450s and N-acetyltransferase activity

      JAPANESE JOURNAL OF CANCER RESEARCH
    63. Aryal, P; Terashita, T; Guengerich, FP; Shimada, T; Oda, Y
      Use of genetically engineered Salmonella typhimurium OY1002/1A2 strain coexpressing human cytochrome P450 1A2 and NADPH-Cytochrome P450 reductase andbacterial O-acetyltransferase in SOS/umu assay

      ENVIRONMENTAL AND MOLECULAR MUTAGENESIS
    64. Sindhu, RK; Sakai, H; Kikkawa, Y
      Effect of hyperoxia on rat pulmonary and hepatic cytochrome P450 monooxygenases

      ARCHIVES OF TOXICOLOGY
    65. Carrillo, JA; Benitez, J
      Clinically significant pharmacokinetic interactions between dietary caffeine and medications

      CLINICAL PHARMACOKINETICS
    66. Welfare, MR; Bassendine, MF; Daly, AK
      The effect of NAT2 genotype and gender on the metabolism of caffeine in nonsmoking subjects

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    67. Hagg, S; Spigset, O; Mjorndal, T; Dahlqvist, R
      Effect of caffeine on clozapine pharmacokinetics in healthy volunteers

      BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
    68. Jorritsma, U; Schrader, E; Klaunick, G; Kapitulnik, J; Hirsch-Ernst, KI; Kahl, GF; Foth, H
      Monitoring of cytochrome P-450 1A activity by determination of the urinarypattern of caffeine metabolites in Wistar and hyperbilirubinemic Gunn rats

      TOXICOLOGY
    69. Aitchison, KJ; Jann, MW; Zhao, JH; Sakai, T; Zaher, H; Wolff, K; Collier, DA; Kerwin, RW; Gonzalez, FJ
      Clozapine pharmacokinetics and pharmacodynamics studied with CYP1A2-null mice

      JOURNAL OF PSYCHOPHARMACOLOGY
    70. Han, XM; Zhou, HH
      Polymorphism of CYP450 and cancer susceptibility

      ACTA PHARMACOLOGICA SINICA
    71. Cheng, ZN; Zhou, HH
      Contribution of genetic variations in estradiol biosynthesis and metabolism enzymes to osteoporosis

      ACTA PHARMACOLOGICA SINICA
    72. Carrillo, JA; Christensen, M; Ramos, SI; Alm, C; Dahl, ML; Benitez, J; Bertilsson, L
      Evaluation of caffeine as an in vivo probe for CYP1A2 using measurements in plasma, saliva, and urine

      THERAPEUTIC DRUG MONITORING
    73. Mihara, K; Suzuki, A; Kondo, T; Yasui, N; Furukori, H; Nagashima, U; Ono, S; Kaneko, S; Otani, K; Inoue, Y
      Effect of a genetic polymorphism of CYP1A2 inducibility on the steady state plasma concentrations of haloperidol and reduced haloperidol in Japanese patients with schizophrenia

      THERAPEUTIC DRUG MONITORING
    74. Eap, CB; Bender, S; Gastpar, M; Fischer, W; Haarmann, C; Powell, K; Jonzier-Perey, M; Cochard, N; Baumann, P
      Steady state plasma levels of the enantiomers of trimipramine and of its metabolites in CYP2D6-, CYP2C19-and CYP3A4/5-phenotyped patients

      THERAPEUTIC DRUG MONITORING
    75. Moller, SE; Larsen, F; Pitsiu, M; Rolan, PE
      Effect of citalopram on plasma levels of oral theophylline

      CLINICAL THERAPEUTICS
    76. Williams, JA; Martin, FL; Muir, GH; Hewer, A; Grover, PL; Phillips, DH
      Metabolic activation of carcinogens and expression of various cytochromes P450 in human prostate tissue

      CARCINOGENESIS
    77. Lampe, JW; King, IB; Li, S; Grate, MT; Barale, KV; Chen, C; Feng, ZD; Potter, JD
      Brassica vegetables increase and apiaceous vegetables decrease cytochrome P450 1A2 activity in humans: changes in caffeine metabolite ratios in response to controlled vegetable diets

      CARCINOGENESIS
    78. Komatsu, T; Yamazaki, H; Shimada, N; Nakajima, M; Yokoi, T
      Roles of cytochromes P450 1A2, 2A6, and 2C8 in 5-fluorouracil formation from tegafur, an anticancer prodrug, in human liver microsomes

      DRUG METABOLISM AND DISPOSITION
    79. Ng, CY; Ghabrial, H; Morgan, DJ; Ching, MS; Smallwood, RA; Angus, PW
      Impaired elimination of propranolol due to right heart failure: Drug clearance in the isolated liver and its relationship to intrinsic metabolic capacity

      DRUG METABOLISM AND DISPOSITION
    80. Sinclair, PR; Gorman, N; Walton, HS; Bement, WJ; Dalton, TP; Sinclair, JF; Smith, AG; Nebert, DW
      CYP1A2 is essential in murine uroporphyria caused by hexachlorobenzene andiron

      TOXICOLOGY AND APPLIED PHARMACOLOGY
    81. Janus, K; Antoszek, J
      The effect of sex and age on caffeine pharmacokinetics in cattle

      RESEARCH IN VETERINARY SCIENCE
    82. Brockmoller, J; Cascorbi, I; Henning, S; Meisel, C; Roots, I
      Molecular genetics of cancer susceptibility

      PHARMACOLOGY
    83. Raaska, K; Neuvonen, PJ
      Ciprofloxacin increases serum clozapine and N-desmethylclozapine: a study in patients with schizophrenia

      EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY
    84. Sindhu, RK; Mitsuhashi, M; Kikkawa, Y
      Induction of cytochrome P-450 1A2 by oxidized tryptophan in Hepa lclc7 cells

      JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
    85. Ueno, T; Tamura, S; Frels, WI; Shou, M; Gonzalez, FJ; Kimura, S
      A transgenic mouse expressing human CYP1A2 in the pancreas

      BIOCHEMICAL PHARMACOLOGY
    86. Dertinger, SD; Lantum, HBM; Silverstone, AE; Gasiewicz, TA
      Effect of 3 '-methoxy-4 '-nitroflavone on benzo[a]pyrene toxicity - Aryl hydrocarbon receptor-dependent and -independent mechanisms

      BIOCHEMICAL PHARMACOLOGY
    87. Longo, V; Ingelman-Sundberg, M; Amato, G; Salvetti, A; Gervasi, PG
      Effect of starvation and chlormethiazole on cytochrome P450s of rat nasal mucosa

      BIOCHEMICAL PHARMACOLOGY
    88. Davydov, DR; Petushkova, NA; Archakov, AI; Hoa, GHB
      Stabilization of P4502B4 by its association with P450 1A2 revealed by high-pressure spectroscopy

      BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS
    89. Lekas, P; Tin, KL; Lee, C; Prokipcak, RD
      The human cytochrome P450 1A1 mRNA is rapidly degraded in HepG2 cells

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    90. Sinclair, PR; Gorman, N; Walton, HS; Bement, WJ; Szakacs, J; Gonzalez, FJ; Dalton, TP; Nebert, DW; Sinclair, JF
      Relative roles of CYP2E1 and CYP1A2 in mouse uroporphyria caused by acetone

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    91. Hudecek, J; Anzenbacherova, E; Anzenbacher, P; Munro, AW; Hildebrandt, P
      Structural similarities and differences of the heme pockets of various P450 isoforms as revealed by resonance Raman spectroscopy

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    92. Hayashi, K; Sakaki, T; Kominami, S; Inouye, K; Yabusaki, Y
      Coexpression of genetically engineered fused enzyme between yeast NADPH-P450 reductase and human cytochrome P450 3A4 and human cytochrome b(5) in yeast

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    93. Shih, H; Pickwell, GV; Quattrochi, LC
      Differential effects of flavonoid compounds on tumor promoter-induced activation of the human CYP1A2 enhancer

      ARCHIVES OF BIOCHEMISTRY AND BIOPHYSICS
    94. Jokinen, MJ; Ahonen, J; Neuvonen, PJ; Olkkola, KT
      The effect of erythromycin, fluvoxamine, and their combination on the pharmacokinetics of ropivacaine

      ANESTHESIA AND ANALGESIA
    95. Bulun, SE; Zeitoun, KM; Kilic, G
      Expression of dioxin-related transactivating factors and target genes in human eutopic endometrial and endometriotic tissues

      AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
    96. Koide, A; Fuwa, K; Furukawa, F; Hirose, M; Nishikawa, A; Mori, Y
      Effect of cigarette smoke on the mutagenic activation of environmental carcinogens by rodent liver

      MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
    97. Kranendonk, M; Fisher, CW; Roda, R; Carreira, F; Theisen, P; Laires, A; Rueff, J; Vermeulen, NPE; Estabrook, RW
      Escherichia coli MTC, a NADPH cytochrome P450 reductase competent mutagenicity tester strain for the expression of human cytochrome P450: Comparison of three types of expression systems

      MUTATION RESEARCH-GENETIC TOXICOLOGY AND ENVIRONMENTAL MUTAGENESIS
    98. Bu-Abbas, A; Clifford, MN; Walker, R; Ioannides, C
      Modulation of hepatic cytochrome P450 activity and carcinogen bioactivation by black and decaffeinated black tea

      ENVIRONMENTAL TOXICOLOGY AND PHARMACOLOGY
    99. Murray, M
      Mechanisms and significance of inhibitory drug interactions involving cytochrome P450 enzymes (Review)

      INTERNATIONAL JOURNAL OF MOLECULAR MEDICINE
    100. Peters, JM; Morishima, H; Ward, JH; Coakley, CJ; Kimura, S; Gonzalez, FJ
      Role of CYP1A2 in the toxicity of long-term phenacetin feeding in mice

      TOXICOLOGICAL SCIENCES


ASDD Area Sistemi Dipartimentali e Documentali, Università di Bologna, Catalogo delle riviste ed altri periodici
Documento generato il 12/12/19 alle ore 15:12:11